Edgestream Partners’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $2.86M | Buy |
6,415
+5,677
| +769% | +$2.53M | 0.08% | 449 |
|
|
2025
Q1 | $358K | Sell |
738
-5,104
| -87% | -$2.47M | 0.01% | 732 |
|
|
2024
Q4 | $2.35M | Buy |
5,842
+3,640
| +165% | +$1.47M | 0.1% | 363 |
|
|
2024
Q3 | $1.02M | Sell |
2,202
-464
| -17% | -$216K | 0.05% | 566 |
|
|
2024
Q2 | $1.25M | Sell |
2,666
-9,988
| -79% | -$4.68M | 0.06% | 466 |
|
|
2024
Q1 | $5.29M | Buy |
12,654
+11,908
| +1,596% | +$4.98M | 0.26% | 92 |
|
|
2023
Q4 | $304K | Sell |
746
-2,656
| -78% | -$1.08M | 0.02% | 718 |
|
|
2023
Q3 | $1.18M | Buy |
3,402
+982
| +41% | +$341K | 0.09% | 344 |
|
|
2023
Q2 | $852K | Buy |
+2,420
| New | +$852K | 0.08% | 394 |
|
|
2022
Q4 | – | Sell |
-5,068
| Closed | -$1.47M | – | 648 |
|
|
2022
Q3 | $1.47M | Buy |
5,068
+2,303
| +83% | +$667K | 0.11% | 233 |
|
|
2022
Q2 | $779K | Buy |
+2,765
| New | +$779K | 0.06% | 360 |
|
|
2022
Q1 | – | Sell |
-1,457
| Closed | -$320K | – | 645 |
|
|
2021
Q4 | $320K | Sell |
1,457
-3,475
| -70% | -$763K | 0.02% | 433 |
|
|
2021
Q3 | $895K | Buy |
+4,932
| New | +$895K | 0.06% | 331 |
|
|
2019
Q2 | – | Sell |
-7,540
| Closed | -$1.39M | – | 291 |
|
|
2019
Q1 | $1.39M | Buy |
+7,540
| New | +$1.39M | 0.2% | 114 |
|
|
2018
Q3 | – | Sell |
-7,789
| Closed | -$1.32M | – | 341 |
|
|
2018
Q2 | $1.32M | Buy |
+7,789
| New | +$1.32M | 0.27% | 125 |
|